title: Association of the ANRS-12126 male circumcision project with HIV levels among men in a South African township: evaluation of effectiveness using cross-sectional surveys.
abstract: BACKGROUND
  Randomized controlled trials have shown that voluntary medical male circumcision (VMMC) reduces HIV infection by 50% to 60% in sub-Saharan African populations; however, little is known about the population-level effect of adult male circumcision (MC) as an HIV prevention method. We assessed the effectiveness of VMMC roll-out on the levels of HIV in the South African township of Orange Farm where the first randomized controlled trial (RCT) to test the effect of VMMC on HIV acquisition was conducted in 2002-2005.
  
  
  RESULTS
  The Bophelo Pele project is a community-based campaign against HIV, which includes the roll-out of free VMMC. A baseline cross-sectional biomedical survey was conducted in 2007-2008 among a random sample of 1,998 men aged 15 to 49 (survey response rate 80.7%). In 2010-2011, we conducted a follow-up random survey among 3,338 men aged 15 to 49 (survey response rate 79.6%) to evaluate the project. Participants were interviewed, blood samples were collected and tested for HIV and recent HIV infection (using the BED HIV incidence assay), and MC status was assessed through a clinical examination. Data were analyzed using multivariate and propensity statistical methods. Owing to the VMMCs performed in the context of the RCT and the Bophelo Pele project, the prevalence rate of adult MC increased from 0.12 (95% CI 0.10-0.14) to 0.53 (95% CI 0.51-0.55). Without these VMMCs, the HIV prevalence rate in 2010-2011 would have been 19% (95% CI 12%-26%) higher (0.147 instead of 0.123). When comparing circumcised and uncircumcised men, no association of MC status with sexual behavior was detected. Among circumcised and uncircumcised men, the proportion consistently using condoms with non-spousal partners in the past 12 months was 44.0% (95% CI 41.7%-46.5%) versus 45.4% (95% CI 42.2%-48.6%) with weighted prevalence rate ratio (wPRR) = 0.94 (95% CI 0.85-1.03). The proportion having two or more non-spousal partners was 50.4% (95% CI 47.9%-52.9%) versus 44.2% (95% CI 41.3%-46.9%) with wPRR = 1.03 (95% CI 0.95-1.10). We found a reduction of BED-estimated HIV incidence rate ranging from 57% (95% CI 29%-76%) to 61% (95% CI 14%-83%) among circumcised men in comparison with uncircumcised men.
  
  
  CONCLUSIONS
  Findings suggest that the roll-out of VMMC in Orange Farm is associated with a significant reduction of HIV levels in the community. The main limitation of the study is that it was not randomized and cannot prove a causal association. The roll-out of VMMC among adults in sub-Saharan Africa should be an international priority and needs to be accelerated to effectively combat the spread of HIV. Please see later in the article for the Editors' Summary.
authors.affiliation: UMRS-1018, CESP, INSERM Villejuif, France ; AP-HP, Hôpital Ambroise Paré, Boulogne, France ; University of Versailles-Saint Quentin, Versailles, France.
authors.forename: Bertran
authors.initials: B
authors.lastname: Auvert
authors.forename: Dirk
authors.initials: D
authors.lastname: Taljaard
authors.forename: Dino
authors.initials: D
authors.lastname: Rech
authors.forename: Pascale
authors.initials: P
authors.lastname: Lissouba
authors.forename: Beverley
authors.initials: B
authors.lastname: Singh
authors.forename: Julie
authors.initials: J
authors.lastname: Bouscaillou
authors.forename: Gilles
authors.initials: G
authors.lastname: Peytavin
authors.forename: Séverin Guy
authors.initials: SG
authors.lastname: Mahiane
authors.forename: Rémi
authors.initials: R
authors.lastname: Sitta
authors.forename: Adrian
authors.initials: A
authors.lastname: Puren
authors.forename: David
authors.initials: D
authors.lastname: Lewis
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D023241:Antiretroviral Therapy, Highly Active; D002944:Circumcision, Male / Q000706:statistics & numerical data*; D003430:Cross-Sectional Studies; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology*; D006306:Health Surveys / Q000706:statistics & numerical data*; D006801:Humans; D007118:Immunoassay; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012725:Sexual Behavior; D013019:South Africa / Q000453:epidemiology; D013997:Time Factors; D055815:Young Adult
references.citation: PLoS Med. 2009 Sep;6(9):e1000109
references.pmid: 19901974
references.citation: PLoS One. 2008 Jun 18;3(6):e2443
references.pmid: 18560581
references.citation: Lancet. 2007 Feb 24;369(9562):657-66
references.pmid: 17321311
references.citation: BMC Infect Dis. 2010 May 27;10:137
references.pmid: 20507545
references.citation: AIDS. 2009 Jan 28;23(3):377-383
references.pmid: 19198042
references.citation: AIDS Res Hum Retroviruses. 2006 Oct;22(10):945-52
references.pmid: 17067263
references.citation: AIDS Res Hum Retroviruses. 2002 Mar 1;18(4):295-307
references.pmid: 11860677
references.citation: Lancet. 2007 Feb 24;369(9562):643-56
references.pmid: 17321310
references.citation: Lancet Infect Dis. 2009 Dec;9(12):747-59
references.pmid: 19926035
references.citation: PLoS Med. 2010 Jul 20;7(7):e1000309
references.pmid: 20652013
references.citation: Lancet. 2009 Jul 18;374(9685):229-37
references.pmid: 19616720
references.citation: PLoS One. 2008 Aug 06;3(8):e2679
references.pmid: 18682725
references.citation: AIDS. 2008 Sep 12;22(14):1841-50
references.pmid: 18753931
references.citation: N Engl J Med. 2009 Mar 26;360(13):1298-309
references.pmid: 19321868
references.citation: BMC Infect Dis. 2007 Mar 13;7:16
references.pmid: 17355625
references.citation: JAMA. 1998 Jul 1;280(1):42-8
references.pmid: 9660362
references.citation: Epidemiology. 2003 Nov;14(6):680-6
references.pmid: 14569183
references.citation: PLoS Med. 2005 Nov;2(11):e298
references.pmid: 16231970
references.citation: PLoS Med. 2006 Jul;3(7):e262
references.pmid: 16822094
references.citation: PLoS One. 2009 Oct 07;4(10):e7368
references.pmid: 19809505
references.citation: J Infect Dis. 2009 Jan 1;199(1):14-9
references.pmid: 19086814
references.citation: Biomed Chromatogr. 2007 Oct;21(10):1095-104
references.pmid: 17582235
references.citation: PLoS One. 2008 May 21;3(5):e2212
references.pmid: 18493593
references.citation: J Acquir Immune Defic Syndr. 2007 Jan 1;44(1):66-70
references.pmid: 17019365
references.citation: AIDS Behav. 2007 May;11(3):341-55
references.pmid: 17053855
references.citation: BMC Infect Dis. 2011 Sep 26;11:253
references.pmid: 21943076